Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting Diastolic Blood Pressure (msDBP) ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2~* Patients who have been treated for hypertension within the 4 weeks prior to - Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2~* All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 4~Exclusion Criteria:~* Severe hypertension~* Pregnant or nursing (lactating) women~* Women of child-bearing potential~* Previous or current diagnosis of heart failure New York Heart Association (NYHA Class II-IV)~* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1~* Uncontrolled Type 1 or Type 2 diabetes mellitus~* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures~* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren 300 mg/Amlodipine 5 mg (Type: EXPERIMENTAL): Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
- Aliskiren 300 mg/Amlodipine 10 mg (Type: EXPERIMENTAL): Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
- Aliskiren 300 mg (Type: ACTIVE_COMPARATOR): Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).